Capital Fund Management S.A. Neurocrine Biosciences Inc Call Options Transaction History

Capital Fund Management S.A.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2020 May 13, 2020	SELL	$75.11 - $113.76 $578,347 - $875,952	-7,700 Reduced 50.33%	7,600 $657,000
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $607,600 - $829,990	7,000 Added 84.34%	15,300 $1.65 Million
Q4 2018 Feb 13, 2019	SELL	$68.32 - $124.36 $2.13 Million - $3.88 Million	-31,200 Reduced 78.99%	8,300 $593,000
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $3.91 Million - $4.97 Million	39,500 New	39,500 $4.86 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $4.46 Million - $6.27 Million	-59,200 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $4.49 Million - $5.47 Million	59,200 New	59,200 $4.91 Million

629

94.2M

692K

406K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.